The mechanisms proposed are various: denosumab might act on RANKL-expressing tumor infiltrating lymphocytes and relieve their anticancer activity that is otherwise blocked by engagement of the ligand with RANK receptor on cells of the tumor microenvironment (138, 139). The gene discussed is TNFSF11; the disease is neoplasm.